Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Cognition Disorders

ClinicalTrials.gov lists 4,607 trials for Cognition Disorders or a narrower condition beneath it. VA Office of Research and Development has the most among industry and government lead sponsors, with 41.

MeSH D003072 Mental Disorders F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 207 Phase 1/2 Phase 1/2 65 Phase 2 Phase 2 371 Phase 2/3 Phase 2/3 41 Phase 3 Phase 3 148 Phase 4 Phase 4 178 Not applicable Not applicable 2,347 Observational Observational 1,248 Phase 1 Phase 1 207 Phase 1/2 Phase 1/2 65 Phase 2 Phase 2 371 Phase 2/3 Phase 2/3 41 Phase 3 Phase 3 148 Phase 4 Phase 4 178 Not applicable Not applicable 2,347 Observational Observational 1,248

Trials per phase (log scale)

1 more section with rows

397 of the 4,607 trials are tagged with Cognition Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Cognition Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Cognition Disorders trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 401

1990: 1 trials (Phase 2 1) 1993: 3 trials (Observational 3) 1995: 1 trials (Observational 1) 1996: 1 trials (Observational 1) 1997: 2 trials (Observational 1, Not applicable 1) 1998: 3 trials (Not applicable 1, Phase 4 1, Phase 2/3 1) 1999: 7 trials (Observational 3, Phase 3 3, Phase 2 1) 2000: 10 trials (Observational 2, Not applicable 2, Phase 4 2, Phase 3 3, Phase 2/3 1) 2001: 10 trials (Observational 4, Not applicable 1, Phase 3 3, Phase 1/2 2) 2002: 13 trials (Observational 3, Phase 4 3, Phase 3 2, Phase 2 4, Phase 1 1) 2003: 26 trials (Observational 9, Not applicable 6, Phase 4 3, Phase 3 5, Phase 2 2, Phase 1 1) 2004: 27 trials (Observational 8, Not applicable 6, Phase 4 3, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 5) 2005: 33 trials (Observational 7, Not applicable 8, Phase 4 6, Phase 3 3, Phase 2/3 1, Phase 2 8) 2006: 42 trials (Observational 9, Not applicable 11, Phase 4 6, Phase 3 2, Phase 2/3 2, Phase 2 8, Phase 1/2 2, Phase 1 2) 2007: 56 trials (Observational 19, Not applicable 17, Phase 4 5, Phase 3 1, Phase 2/3 1, Phase 2 8, Phase 1/2 1, Phase 1 4) 2008: 58 trials (Observational 15, Not applicable 13, Phase 4 7, Phase 3 5, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 6) 2009: 96 trials (Observational 30, Not applicable 19, Phase 4 5, Phase 3 10, Phase 2/3 2, Phase 2 12, Phase 1/2 1, Phase 1 17) 2010: 80 trials (Observational 21, Not applicable 26, Phase 4 11, Phase 3 2, Phase 2/3 2, Phase 2 9, Phase 1 9) 2011: 112 trials (Observational 30, Not applicable 32, Phase 4 12, Phase 3 9, Phase 2 20, Phase 1 9) 2012: 119 trials (Observational 36, Not applicable 45, Phase 4 3, Phase 3 8, Phase 2/3 3, Phase 2 15, Phase 1/2 1, Phase 1 8) 2013: 106 trials (Observational 33, Not applicable 39, Phase 4 11, Phase 3 7, Phase 2/3 1, Phase 2 8, Phase 1/2 2, Phase 1 5) 2014: 144 trials (Observational 36, Not applicable 66, Phase 4 8, Phase 3 10, Phase 2/3 3, Phase 2 12, Phase 1/2 1, Phase 1 8) 2015: 169 trials (Observational 39, Not applicable 88, Phase 4 13, Phase 3 2, Phase 2/3 3, Phase 2 14, Phase 1/2 2, Phase 1 8) 2016: 191 trials (Observational 53, Not applicable 100, Phase 4 10, Phase 3 5, Phase 2 13, Phase 1/2 2, Phase 1 8) 2017: 248 trials (Observational 60, Not applicable 138, Phase 4 9, Phase 3 4, Phase 2/3 3, Phase 2 24, Phase 1/2 3, Phase 1 7) 2018: 265 trials (Observational 79, Not applicable 137, Phase 4 4, Phase 3 11, Phase 2/3 2, Phase 2 20, Phase 1/2 3, Phase 1 9) 2019: 275 trials (Observational 77, Not applicable 143, Phase 4 9, Phase 3 7, Phase 2 18, Phase 1/2 8, Phase 1 13) 2020: 263 trials (Observational 91, Not applicable 132, Phase 4 4, Phase 3 5, Phase 2/3 3, Phase 2 16, Phase 1/2 3, Phase 1 9) 2021: 375 trials (Observational 107, Not applicable 193, Phase 4 6, Phase 3 7, Phase 2/3 4, Phase 2 34, Phase 1/2 4, Phase 1 20) 2022: 364 trials (Observational 112, Not applicable 199, Phase 4 8, Phase 3 7, Phase 2/3 1, Phase 2 19, Phase 1/2 7, Phase 1 11) 2023: 367 trials (Observational 98, Not applicable 221, Phase 4 8, Phase 3 4, Phase 2 19, Phase 1/2 3, Phase 1 14) 2024: 401 trials (Observational 97, Not applicable 254, Phase 4 8, Phase 3 3, Phase 2/3 2, Phase 2 28, Phase 1/2 3, Phase 1 6) 2025: 389 trials (Observational 84, Not applicable 244, Phase 4 6, Phase 3 11, Phase 2/3 2, Phase 2 26, Phase 1/2 6, Phase 1 10)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 321
2025 389
2024 401
2023 367
2022 364
2021 375
2020 263
2019 275
2018 265
2017 248

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 370 trials starting in 2026 and about 380 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 532 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 2,521 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Cognition Disorders trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 207
Phase 1/2 65
Phase 2 371
Phase 2/3 41
Phase 3 148
Phase 4 178
Not applicable 2,347
Observational 1,248
Expanded access 2

How many Cognition Disorders trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 277
Recruiting 725
Enrolling by invitation 78
Active, not recruiting 238
Completed 2,218

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Cognition Disorders trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
VA Office of Research and Development 41

Which drugs are being tested for Cognition Disorders? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PROPOFOL 31
DEXMEDETOMIDINE 25
PMI-150 (intranasal ketamine) 13

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Donepezil HCI (drug) 39
Control (placebo) group 24
memantine ER 23
Aerobic exercise 22
Exercise 22

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Cognition Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Other 1,914 2
Death 635 22
Lungs problems 578 1
Chest Pain 403 6
Stroke 389 12

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Cognition Disorders? (4,996)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Assessing cognitive impairment in chronic pain: a cross-sectional study with healthy controls. Disability and rehabilitation 2025 Yes
Tele-neuropsychological multidomain assessment in Italian people with cognitive disorders: Reliability and user satisfaction. Journal of Alzheimer's disease : JAD 2025 Yes
Relationship between cognitive impairments and psychopathological symptoms in female schizophrenia subsequent to 8 weeks treatment with antipsychotic drugs. BMC psychiatry 2025 Yes
Observational protocol on neuropsychological disorders in cardiovascular disease for holistic prevention and treatment. Future cardiology 2025 Yes
Neuropsychological test performance and self-reported cognitive functioning associated with work-related outcomes in occupationally active cancer survivors with cognitive complaints. Journal of cancer survivorship : research and practice 2024 Yes

Showing 5 of 4,996 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages